✦ LIBER ✦

Clinical recommendations for the use of lapatinib ditosylate plus capecitabine for patients with advanced or metastatic HER2-positive breast cancer

✍ Scribed by Raymond D SNYDER; Frances M BOYLE; Arlene CHAN; Paul S CRAFT; Richard DE BOER; Paul N MAINWARING; Nicole J McCARTHY; Nicholas R WILCKEN

Book ID: 111318734
Publisher: John Wiley and Sons
Year: 2009
Tongue: English
Weight: 454 KB
Volume: 5
Category: Article
ISSN: 1743-7555
DOI: 10.1111/j.1743-7563.2009.01194.x

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Randomized phase II study of lapatinib p

Randomized phase II study of lapatinib plus capecitabine or lapatinib plus topotecan for patients with HER2-positive breast cancer brain metastases

✍ Nancy U. Lin; Wolfgang Eierman; Richard Greil; Mario Campone; Bella Kaufman; Kla 📂 Article 📅 2011 🏛 Springer US 🌐 English ⚖ 189 KB

PCN15 SYSTEMATIC REVIEW OF LAPATINIB PLU

PCN15 SYSTEMATIC REVIEW OF LAPATINIB PLUS LETROZOLE WITH OTHER FIRST LINE TREATMENTS FOR HORMONE POSITIVE (HR+) HER2+ ADVANCED OR METASTATIC BREAST CANCER (MBC)

✍ R Riemsma; CA Forbes; M Amonkar; K Lykopoulos; JR Diaz; J Kleijnen; DW Rea 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 79 KB

Sorafenib in Combination With Capecitabi

Sorafenib in Combination With Capecitabine: An Oral Regimen for Patients With HER2-Negative Locally Advanced or Metastatic Breast Cancer

✍ Baselga, J.; Segalla, J. G. M.; Roche, H.; del Giglio, A.; Pinczowski, H.; Cirue 📂 Article 📅 2012 🏛 American Society of Clinical Oncology 🌐 English ⚖ 177 KB

Phase II trial of a novel capecitabine d

Phase II trial of a novel capecitabine dosing schedule in combination with lapatinib for the treatment of patients with HER2-positive metastatic breast cancer

✍ Devika Gajria; Joseph Gonzalez; Kimberly Feigin; Sujata Patil; Carol Chen; Maria 📂 Article 📅 2011 🏛 Springer US 🌐 English ⚖ 219 KB

Trastuzumab plus docetaxel with or witho

Trastuzumab plus docetaxel with or without capecitabine as first-line therapy for HER2-positive locally advanced or metastatic breast cancer: a randomised Phase II study

✍ A. Wardlev; A. Anton-Torres; X. Pivot; F. Morales-Vasquez; L. Zetina; M. de Fati 📂 Article 📅 2008 🏛 Elsevier Science 🌐 English ⚖ 69 KB

Efficacy, safety, pharmacokinetics and b

Efficacy, safety, pharmacokinetics and biomarker findings in patients with HER2-positive advanced or metastatic breast cancer treated with lapatinib in combination with capecitabine: results from 51 Japanese patients treated in a clinical study

✍ Iwata, Hiroji; Fujii, Hirofumi; Masuda, Norikazu; Mukai, Hirofumi; Nishimura, Yu 📂 Article 📅 2013 🏛 Springer Japan 🌐 English ⚖ 300 KB